查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1840848

伴侶動物術後疼痛管理治療市場（按產品類型、動物類型、給藥途徑和最終用戶分類）－2025-2032年全球預測

Companion Animal Postoperative Pain Management Therapeutics Market by Product Type, Animal Type, Route Of Administration, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，伴侶動物術後疼痛管理治療市場規模將成長 3.2845 億美元，複合年成長率為 10.34%。

關鍵市場統計數據
基準年 2024 1.4946億美元
預計年份：2025年 1.6465億美元
預測年份 2032 3.2845億美元
複合年成長率 (%) 10.34%

權威指導，引領伴侶動物術後疼痛治療領域不斷發展的臨床、技術和商業性動態。

伴侶動物的術後疼痛管理已從單一的臨床問題發展成為涵蓋藥理學、手術方案設計和主人教育的多學科交叉領域。臨床醫師如今需要在療效、安全性和飼主依從性之間取得平衡，同時也要應對鴉片類藥物使用方面的監管審查，並不斷拓展替代藥物選擇。因此，治療決策不僅要考慮犬貓的急性鎮痛需求，還要兼顧長期福利、診所營運成本和供應鏈實際情況。

同時，緩釋性局部麻醉劑和經皮系統等製劑技術的進步正在改變圍手術全期工作流程，使鎮痛效果更可預測，給藥次數更少。這些技術發展與不斷變化的臨床環境相輔相成。專科醫院、日益成長的線上藥局管道以及多中心獸醫集團正在影響產品的處方、配藥和監測方式。因此，相關人員必須整合臨床證據、給藥途徑偏好和最終使用者行為，才能設計出既具有商業性可行性又具有臨床療效的策略。

報告的執行摘要將這些動態置於犬貓術後疼痛治療的整體背景下進行分析，重點闡述了影響產品應用的臨床因素、產品創新軌跡以及產業結構的轉變。該報告旨在為決策者提供一個綜合觀點，以支持其在研發、監管溝通和商業性執行等方面的戰術性規劃。

不斷發展的臨床通訊協定、配方突破和不斷變化的分銷管道如何重新定義伴侶動物的術後疼痛管理

由於臨床、技術和分銷管道的創新融合，伴侶動物術後疼痛管理的格局正在發生顯著變化。臨床實務正在加速採用多模態鎮痛通訊協定，該方案結合了局部麻醉劑、非類固醇消炎劑和選擇性鴉片類藥物，旨在最佳化疼痛管理並減少副作用。這種轉變標誌著圍手術手術全期計畫正朝著基於對疼痛病理生理學更深入理解和實證實踐的個體化方向發展。

在技​​術方面，製劑科學正推動長效局部麻醉劑以及經皮和注射給藥系統的改進，從而減少給藥頻率並提高患者依從性。這些進步使得患者能夠順利從醫院過渡到居家醫療，並為以便捷性和持續療效為核心的新產品定位開闢了機會。同時，非類固醇消炎劑化學和標籤的安全創新，以及臨床醫生教育的改進，正在緩解人們對不利事件的擔憂，而這些擔憂過去一直限制著積極的術後管理。

在商業方面，除了傳統的獸醫診所和零售藥局外，隨著線上藥局的興起，分銷和獲取管道也在發生變化。這種通路多元化迫使製造商採用更複雜的供應鏈和定價策略。此外，強調鴉片類藥物管理和上市後藥物安全檢測的監管趨勢也在重塑產品生命週期規劃。總而言之，這些變化創造了一個更複雜但也充滿機會的環境，成功取決於臨床可信度、製劑差異化和基於通路的商業化。

2025年關稅對伴侶動物鎮痛藥的藥品採購、定價結構和庫存策略的綜合影響

2025年累積關稅的實施，為動物用藥品相關人員的供應鏈和成本管理帶來了新的複雜性。關稅主導的成本壓力迫使製造商和經銷商重新評估籌資策略，優先考慮區域供應安全，並盡可能考慮將部分生產環節遷回國內或近岸。因此，採購團隊越來越注重供應商多元化，以降低產地集中和關稅波動帶來的風險。

這些關稅的影響不僅限於直接投入成本，還波及價格談判、庫存管理以及與終端用戶管道的合約結構。獸醫診所和醫療機構，尤其是規模較小的全科診所，必須重新調整採購時機和庫存緩衝，以降低價格波動的影響。同時，連鎖藥局和大型專科診所則擁有更大的議價能力，可以協商基於銷售的協議，從而部分抵銷關稅帶來的成本上漲。

此外，關稅環境正在加速簡化製劑配方和延長保存期限產品的討論，以降低物流成本。過渡策略包括優先考慮保存期限更長的產品，增加緩釋性的使用以減少重複訂購頻率，以及調整臨床通訊協定，優先考慮那些能夠平衡給藥複雜性和供應穩定性的治療方法。最終，2025年的關稅趨勢凸顯了整合商業和供應鏈規劃的必要性，以確保伴侶動物術後鎮痛藥物的可近性和可負擔性。

差異化細分分析揭示了產品類型、動物種類、給藥途徑和管道結構如何獨特地影響臨床應用和商業策略。

對術後鎮痛生態系統的詳細細分揭示了臨床應用、製劑偏好和管道動態方面的關鍵差異，這些差異驅動著不同的商業策略。就產品類型而言，該領域主要圍繞著局部麻醉劑、非類固醇消炎劑)和鴉片類藥物展開，每種藥物都具有獨特的治療作用和監管考慮。在局部麻醉劑中，Bupivacaine和Lidocaine等藥物用於術中和術後即刻鎮痛，緩釋性的進步提升了它們的戰略價值。 NSAIDs，包括卡洛芬、德拉考昔、非羅考昔和美洛昔康等分子，儘管安全性和給藥方式有所不同，但仍是術後疼痛和發炎管理的基石。Buprenornhine、Fentanyl和曲馬多等非類固醇消炎劑藥物在中度至重度疼痛的治療中仍然發揮作用，但它們受到日益嚴格的監管框架的約束，這影響著處方行為。

貓和狗在藥理學和行為學方面存在顯著差異，這些差異會影響藥物的選擇、給藥方式以及飼主的指導。例如，貓需要特別關注其對非類固醇抗發炎藥（NSAIDs）的耐受性和鴉片類藥物的選擇，而狗則可以受益於多種核准的NSAIDs以及成熟的手術全期用藥方案。給藥途徑對用藥的接受度和依從性有顯著影響。注射劑是醫院圍手術全期管理的首選；口服藥物支持居家治療；外用藥物可緩解局部疼痛，且全身暴露量極小；經皮吸收貼片可提供持久鎮痛，適合門診治療，也方便飼主使用。

終端用戶細分影響藥物取得、處方模式和銷售點動態。線上藥局擴大了藥品供應範圍，提高了便利性，但也帶來了監管合規性和臨床醫生參與的考量。獸醫醫院和診所，包括全科診所和專科醫院，是圍手術全期計劃和現場管理的關鍵決策點，而獸用零售藥房（包括連鎖店和獨立藥房）在藥品上市初期的配藥和諮詢方面發揮著關鍵作用。這些相互交織的細分維度為研發優先事項、商業性目標和教育推廣提供了依據，確保產品定位符合每個相關人員的臨床實際情況和物流偏好。

在全球市場中，監管、臨床實踐和通路成熟度的區域差異將決定不同的市場進入、商業化和生命週期策略。

區域動態對法規環境、分銷架構和臨床實踐規範有著顯著影響，從而在美洲、中東和非洲以及亞太地區創造了獨特的商業機會。在美洲，完善的獸醫基礎設施和寵物主人的高消費水準促進了先進配方和綜合圍手術全期通訊協定的快速普及。在這種環境下，透過便利性、安全性以及能夠引起臨床醫生和寵物飼主飼主共鳴的顯著療效來實現差異化競爭優勢至關重要。

在歐洲、中東和非洲，由於監管差異和市場成熟度不同，藥物的採用率也有差異。西歐市場通常採用先進的臨床通訊協定，並優先考慮藥物安全檢測和標籤，而其他一些地區的市場則更注重成本控制和新療法的分階段引入。強調動物用藥品安全和抗菌藥物管理的法律規範也會影響鴉片類藥物的使用和非類固醇消炎劑（NSAID）的標籤，進而影響產品推廣和教育重點。

亞太地區融合了快速發展的伴侶動物護理標準、對專業獸醫服務的巨額投資以及迅速擴張的線上藥局網路。該地區一些國家正在加速採納臨床指南，並積極接受能夠減少用藥劑量和支持門診治療的製劑創新。然而，供應鏈的複雜性和區域監管的特殊性要求制定有針對性的打入市場策略，該策略需考慮註冊時間、進口要求和通路合作夥伴的選擇。了解這些區域差異對於使臨床證據和商業化計劃與當地的期望和限制相符至關重要。

成熟製造商、專業創新者和策略夥伴如何推動術後鎮痛領域的臨床應用、通路進入和產品差異化

伴侶動物術後鎮痛治療領域的競爭格局呈現出多元化的特點，既有成熟的製藥企業，也有專注於動物用藥品創新領域的專業公司，以及致力於製劑和給藥方式創新的新興生物製藥參與企業。現有企業利用其廣泛的分銷網路和與臨床醫生的良好關係，在醫院和零售通路站穩腳跟；而專業企業則憑藉新型緩釋技術、經皮給藥系統以及簡化圍手術全期流程的產品支援服務，實現差異化競爭。

策略活動的核心在於展現臨床差異化優勢、在醫院系統中佔據有利的處方地位，以及與連鎖獸醫診所和線上經銷商建立夥伴關係。此外，那些大力投資上市後安全性監測和臨床醫師教育的公司往往能夠贏得執業醫師的信任，因為執業醫師更重視可預測的風險效益比。新參與企業和規模較小的專科公司通常採取快速上市策略，利用密集的臨床試驗、關鍵意見領袖互動和數位化教育平台來加速產品推廣。

合作模式日益普遍，授權、共同促銷和分銷協議能夠幫助企業更快進入市場，克服不同地區的監管障礙。隨著商業化管道的日益細分，那些能夠根據終端用戶偏好調整產品設計的公司——例如，針對專科醫院提供注射用緩釋性，針對全科醫生提供便捷的口服方案——將更有利於贏得臨床顧客購買傾向率並獲得長期收益。

製造商和經銷商可透過切實可行的策略性舉措，協調證據產生、配方設計、供應彈性和通路互動，從而獲得競爭優勢。

為確保永續優勢，產業領導者應採取連貫的、以證據主導的策略，將產品創新與臨床通訊協定和通路實際情況結合。首先，應優先產生多模態臨床證據，證明局部麻醉劑、非類固醇消炎劑和選擇性鴉片類藥物的聯合應用如何改善患者預後並降低併發症率。高品質、融入實務的臨床試驗和真實世界資料收集，既能增強對醫院和診所的價值提案，又能支持負責任的藥物管理理念。

第二，使製劑策略與終端使用者的工作流程相契合，提供緩釋性和經皮方案，以減輕給藥負擔並提高依從性，並確保注射劑的特性支持高效的手術全期用藥。根據全科診所和專科醫院的需求客製化包裝、標籤和教育材料，可以提高藥物接受度並減少臨床診療過程中的摩擦。第三，建立具有韌性的供應鏈模式，考慮關稅風險，實現採購多元化，並制定緊急庫存策略，以在全球供應中斷期間維持供應的連續性。

第四，投資於通路專屬的商業模式，平衡與線上藥局的合作與深度臨床夥伴關係。數位化教育、整合遠端醫療的處方支援以及面向診所的決策支援工具能夠促進產品的合理使用。最後，納入健全的藥物安全檢測和鴉片類藥物管理計劃，以滿足監管要求並建立醫務人員的信任。這些措施的結合能夠幫助企業將臨床信譽轉化為永續的商業性業績，同時以負責任的方式推進患者照護。

一項結合臨床醫生訪談、文獻綜述和主導細分的場景分析的穩健的混合方法研究途徑，檢驗了該領域的相關見解。

本執行摘要的研究結合了多種定性和定量方法，旨在全面了解臨床、商業和監管動態。主要研究包括對獸醫、全科醫生、處方集管理人員和分銷主管進行結構化訪談，以了解實際的處方行為、通路偏好和營運限制。次要研究包括對同行評審的獸醫臨床文獻、監管指導文件、公開的製劑資訊和藥物安全檢測報告進行橫斷面檢索，以確定產品層面的考慮因素和安全性概況。

分析方法包括交叉細分綜合分析，旨在描繪產品類型、動物種類、給藥途徑和終端用戶管道之間的相互作用；以及情境分析，以評估供應鏈中斷和關稅的影響。我們與臨床醫生和商業性相關人員舉辦檢驗研討會，檢驗了假設，並完善了產品定位和市場推廣策略的相關建議。在調查方法和資料來源方面，我們專注於整合多源數據，以減少單一來源偏差，並確保研究結果與不同區域環境的相關性。

本文簡明扼要地總結了臨床創新、監管預期和商業性執行之間的整合，並概述了未來的策略重點。

伴侶動物術後疼痛管理正處於曲折點，臨床最佳實踐、製劑技術的進步以及商業分銷模式的轉變，為相關人員創造了新的機會和挑戰。多模式鎮痛的興起，以及緩釋性局部麻醉劑和經皮給藥系統的創新，正在提升我們提供有效且便於飼主使用的疼痛管理方案的能力。同時，監管環境對鴉片類藥物管理的重視以及不斷變化的收費體系，也對供應鏈和臨床管治提出了更高的要求。

要成功駕馭這個市場格局，需要將嚴謹的臨床證據與通路導向的商業化策略和靈活的籌資策略結合。那些投資於臨床醫生參與、研發能夠解決實際問題的差異化製劑以及建立健全的藥物安全檢測體系的公司，將更有能力影響處方行為並實現長期應用。簡而言之，伴侶動物術後鎮痛的未來將惠及那些擁有臨床信譽、卓越運作以及明確關注醫護人員和寵物飼主需求的機構。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 開發用於犬貓術後長期鎮痛的脂質體Bupivacaine製劑
  • 採用整合非類固醇抗發炎藥和局部阻斷的、減少鴉片類藥物使用的多維度疼痛管理通訊協定
  • 穿戴式感測器技術在遠端監測寵物術後疼痛行為的應用
  • 人們對再生醫學輔助手段（例如幹細胞）促進術後復健的興趣日益濃厚。
  • 越來越多的獸醫開始使用大麻二酚製劑來控制伴侶動物在手術過程中的疼痛。
  • 將遠端醫療平台整合到術後護理中，用於虛擬疼痛評估和飼主教育。
  • 開發基於藥物基因組學的給藥工具，用於獸醫實踐中個體化鎮痛方案。
  • 監管方面的進展將加快有條件許可下新型獸用止痛藥的核准

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 伴侶動物術後疼痛管理治療市場（依產品類型分類）

  • 局部麻醉劑
    • Bupivacaine
    • Lidocaine
  • 非類固醇消炎劑
    • 卡洛芬
    • 德拉考昔
    • 非羅昔布
    • 美洛昔康
  • 鴉片類藥物
    • Buprenornhine
    • Fentanyl
    • 曲馬多

9. 伴侶動物術後疼痛管理治療市場（依動物類型分類）

  • 貓
  • 狗

10. 伴侶動物術後疼痛管理治療市場（依給藥途徑分類）

  • 注射
  • 口服
  • 外用
  • 經皮吸收貼片

11. 伴侶動物術後疼痛管理治療市場（依最終使用者分類）

  • 網路藥房
  • 獸醫醫院和診所
    • 一般醫療
    • 專科醫院
  • 獸藥零售藥房
    • 連鎖藥局
    • 獨立藥房

12. 伴侶動物術後疼痛管理治療市場（依地區分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

13. 伴侶動物術後疼痛管理治療市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國伴侶動物術後疼痛管理治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Zoetis Inc.
    • Elanco Animal Health Incorporated
    • Merck & Co., Inc.
    • Boehringer Ingelheim International GmbH
    • Dechra Pharmaceuticals PLC
    • Norbrook Laboratories Ltd.
    • Vetoquinol SA
    • Ceva Sante Animale SA
    • Virbac SA
    • Johnson & Johnson Services, Inc.
Product Code: MRR-221461476CB6

The Companion Animal Postoperative Pain Management Therapeutics Market is projected to grow by USD 328.45 million at a CAGR of 10.34% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 149.46 million
Estimated Year [2025] USD 164.65 million
Forecast Year [2032] USD 328.45 million
CAGR (%) 10.34%

An authoritative orientation to the evolving clinical, technological, and commercial dynamics shaping postoperative pain therapies for companion animals

Companion animal postoperative pain management has evolved from a narrow clinical concern into a multidisciplinary imperative that spans pharmacology, surgical protocol design, and client education. Clinicians now balance efficacy, safety, and owner compliance while navigating heightened regulatory scrutiny around opioid use and a growing portfolio of alternatives. Consequently, therapeutic decision-making reflects not only the acute analgesic needs of cats and dogs but also longer-term welfare considerations, practice economics, and supply chain realities.

In parallel, advances in formulation technologies, such as extended-release local anesthetics and transdermal systems, are changing perioperative workflows and enabling more predictable analgesia with fewer administrations. These technical developments intersect with evolving practice settings; specialty hospitals, growing online pharmacy channels, and multi-site veterinary groups shape how products are prescribed, dispensed, and monitored. Therefore, stakeholders must synthesize clinical evidence, route-of-administration preferences, and end-user behaviors to design commercially viable and clinically effective strategies.

This report executive summary situates these dynamics within the broader therapeutic landscape for postoperative pain in cats and dogs, highlighting the clinical drivers, product innovation trajectories, and structural industry shifts that influence adoption. The aim is to equip decision-makers with an integrated perspective that supports tactical planning across R&D, regulatory engagement, and commercial execution.

How clinical protocol evolution, formulation breakthroughs, and shifting distribution channels are redefining postoperative pain management for companion animals

The landscape of postoperative pain management in companion animals is undergoing transformative shifts driven by converging clinical, technological, and distribution innovations. Clinically, there is an accelerating adoption of multimodal analgesia protocols that combine local anesthetics, non-steroidal anti-inflammatory drugs, and selective opioid use to optimize pain control while mitigating side effects. This shift represents a more nuanced appreciation of pain pathophysiology and a move toward individualized perioperative plans anchored in evidence-based practice.

Technologically, formulation science is delivering longer-acting local anesthetics and improved transdermal and injectable delivery systems, which reduce dosing frequency and improve owner adherence. These advances enable smoother transitions from hospital to home care and open opportunities for novel product positioning centered on convenience and sustained efficacy. Simultaneously, safety-focused innovation in NSAID chemistry and labeling, combined with better clinician education, is reducing adverse-event concerns that historically limited aggressive postoperative management.

On the commercial side, distribution and access are changing as online pharmacies gain traction alongside traditional veterinary hospitals and retail pharmacies. This diversification of channels compels manufacturers to adopt more sophisticated supply chain and pricing strategies. In addition, regulatory trends emphasizing opioid stewardship and post-market pharmacovigilance are reshaping product lifecycle planning. Taken together, these shifts create a more complex but opportunity-rich environment where clinical credibility, formulation differentiation, and channel-aligned commercialization determine success.

The compound effects of 2025 tariff measures on pharmaceutical sourcing, pricing architecture, and inventory strategies for companion animal analgesics

The introduction of cumulative tariffs in 2025 has added a new layer of complexity to supply chains and cost management for veterinary pharmaceutical stakeholders. Tariff-driven cost pressures have prompted manufacturers and distributors to reevaluate sourcing strategies, prioritize regional supply security, and consider onshoring or nearshoring certain manufacturing steps where feasible. As a result, procurement teams are increasingly focused on supplier diversification to reduce exposure to concentrated origin risks and tariff volatility.

These tariff effects propagate beyond direct input costs; they influence pricing negotiations with end-user channels, inventory management practices, and the structure of contractual agreements. Veterinary hospitals and clinics, especially smaller general practices, have had to reassess purchasing cadence and inventory buffers to mitigate price fluctuations. Meanwhile, chain pharmacies and larger specialty hospitals possess greater leverage to negotiate volume-based arrangements that can partially offset tariff-related cost increases.

Moreover, the tariff environment has accelerated conversations about formulation simplification and longer-dated products to rationalize logistics expenses. Transitional strategies include prioritizing products with durable shelf life, increasing the use of extended-release formulations to reduce reorder frequency, and aligning clinical protocols to favor therapies that balance administration complexity with supply resilience. Ultimately, tariff dynamics in 2025 have underscored the need for integrated commercial and supply-chain planning to maintain access and affordability for postoperative pain therapies in companion animals.

A differentiated segmentation analysis revealing how product types, animal species, administration routes, and channel structures uniquely shape clinical adoption and commercial strategy

A granular segmentation view of the postoperative analgesia ecosystem reveals critical variances in clinical use, formulation preference, and channel dynamics that drive differentiated commercial strategies. When considering product type, the field is structured around local anesthetics, non-steroidal anti-inflammatory drugs, and opioids, each with distinct therapeutic roles and regulatory considerations. Within local anesthetics, agents such as bupivacaine and lidocaine address intraoperative and immediate postoperative pain control, and advances in extended-release formulations magnify their strategic value. Non-steroidal anti-inflammatory drugs encompass molecules including carprofen, deracoxib, firocoxib, and meloxicam, which form the backbone of postoperative pain and inflammation management with varying safety profiles and dosing paradigms. Opioids such as buprenorphine, fentanyl, and tramadol maintain a role for moderate to severe pain but face increasingly stringent stewardship frameworks that influence prescribing behavior.

Animal type further stratifies clinical pathways, as cats and dogs exhibit important pharmacologic and behavioral differences that affect agent selection, dosing, and owner instructions. Cats, for instance, require particular attention to certain NSAID tolerability and opioid choice, while dogs benefit from a broader array of approved NSAID options and established perioperative pathways. Route of administration exerts a powerful influence on adoption and compliance; injectable formulations are favored for perioperative control in hospital settings, oral agents support home-based continuation of therapy, topical options address localized pain with lower systemic exposure, and transdermal patches offer extended analgesia suited to outpatient care and owner convenience.

End-user segmentation shapes access, prescribing patterns, and point-of-sale dynamics. Online pharmacies expand reach and convenience but bring considerations around regulatory compliance and clinician engagement. Veterinary hospitals and clinics, including general practices and specialty hospitals, serve as primary decision points for perioperative planning and on-site administration, while veterinary retail pharmacies-both chain and independent-play a critical role in dispensing and counseling at the point of release. These layered segmentation dimensions inform R&D prioritization, commercial targeting, and educational outreach, ensuring that product positioning aligns with the clinical realities and logistical preferences of each stakeholder group.

Regional variations in regulation, clinical practices, and channel maturity that dictate differentiated entry, commercialization, and lifecycle strategies across global markets

Regional dynamics materially influence regulatory environments, distribution architectures, and clinical practice norms, creating divergent opportunity sets across the Americas, Europe Middle East and Africa, and Asia-Pacific. In the Americas, established veterinary practice infrastructures and high pet-owner spend support rapid uptake of advanced formulations and comprehensive perioperative protocols, while reimbursement models remain largely private-pay and therefore sensitive to perceived value. This environment favors differentiation through convenience, proven safety, and demonstrable outcomes that resonate with clinicians and owners alike.

Across Europe, the Middle East and Africa, regulatory heterogeneity and varying market maturity produce a patchwork of adoption rates. Western European markets often mirror advanced clinical protocols and prioritize pharmacovigilance and labeling harmonization, whereas some markets in the broader region emphasize cost containment and incremental introductions of novel therapies. Regulatory frameworks that emphasize veterinary drug safety and antimicrobial stewardship also shape opioid access and NSAID labeling, influencing product rollouts and educational priorities.

Asia-Pacific presents a mix of fast-evolving companion animal care standards, significant investment in specialty veterinary services, and a rapidly expanding online pharmacy footprint. Certain countries in the region are accelerating clinical guideline adoption and are highly receptive to formulation innovations that reduce dosing frequency and support outpatient care. However, supply-chain complexity and local regulatory idiosyncrasies require targeted market-entry strategies that account for registration timelines, import requirements, and channel partner selection. Navigating these regional nuances is essential for aligning clinical evidence packages and commercialization plans with local expectations and constraints.

How incumbent manufacturers, specialty innovators, and strategic partners converge to drive clinical adoption, channel access, and product differentiation in postoperative analgesia

Competitive dynamics in the companion animal postoperative pain therapeutic area are characterized by a mix of established pharmaceutical manufacturers, specialty veterinary pharma innovators, and emerging biopharmaceutical entrants focused on formulation and delivery innovation. Incumbent players leverage broad distribution networks and clinician relationships to maintain a presence in hospital and retail channels, while specialized companies differentiate through novel extended-release technologies, transdermal systems, and product support services that simplify perioperative workflows.

Strategic activity centers on demonstrating clinical differentiation, securing favorable formulary positions within hospital systems, and forging partnerships with veterinary chains and online distributors. Additionally, companies that invest in robust post-market safety surveillance and targeted clinician education tend to gain trust among practitioners who prioritize predictable risk-benefit profiles. New entrants and smaller specialists often adopt nimble go-to-market approaches, using focused clinical pilots, key opinion leader engagement, and digital education platforms to accelerate adoption.

Collaborative models are increasingly common, with licensing, co-promotion, and distribution agreements enabling faster market access across regions with divergent regulatory hurdles. As commercialization becomes more channel-specific, companies that align product design with end-user preferences-such as favoring injectable extended-release formulations for specialty hospitals or convenient oral regimens for general practices-are better positioned to capture clinical mindshare and long-term loyalty.

Practical strategic moves for manufacturers and distributors to align evidence generation, formulation design, supply resilience, and channel engagement to gain competitive advantage

Industry leaders should adopt a coherent, evidence-driven strategy that aligns product innovation with clinical protocols and channel realities to secure sustainable advantage. First, prioritize multimodal clinical evidence generation that demonstrates how combinations of local anesthetics, NSAIDs, and selective opioid use improve patient outcomes and reduce complication rates. High-quality, practice-embedded trials and real-world data capture will strengthen value propositions for hospitals and clinics while supporting responsible stewardship narratives.

Second, align formulation strategy with end-user workflows by offering extended-release and transdermal options where they reduce dosing burden and improve compliance, and by ensuring injectable profiles support efficient perioperative use. Tailoring packaging, labeling, and educational materials to the needs of general practices versus specialty hospitals will improve uptake and reduce friction at the point of care. Third, develop resilient supply-chain models that account for tariff risk, favor diversified sourcing, and include contingency inventory strategies to maintain continuity of supply during global disruptions.

Fourth, invest in channel-specific commercial models that balance online pharmacy engagement with deep clinical partnerships. Digital education, telemedicine-aligned prescribing support, and clinic-facing decision aids can enhance appropriate product use. Finally, incorporate robust pharmacovigilance and opioid stewardship programs to meet regulatory expectations and build practitioner trust. Together, these measures will enable companies to convert clinical credibility into durable commercial performance while responsibly advancing patient care.

A robust mixed-methods research approach integrating clinician interviews, literature synthesis, and segmentation-driven scenario analysis to validate sector insights

The research underpinning this executive summary combines multiple qualitative and quantitative approaches to ensure a comprehensive understanding of clinical, commercial, and regulatory dynamics. Primary research included structured interviews with veterinary surgeons, general practitioners, formulary managers, and distribution executives to capture real-world prescribing behaviors, channel preferences, and operational constraints. Secondary research encompassed a cross-section of peer-reviewed veterinary clinical literature, regulatory guidance documents, and publicly available formulation and pharmacovigilance reports to contextualize product-level considerations and safety profiles.

Analytical techniques included cross-segmentation synthesis to map how product types, animal species, administration routes, and end-user channels interact, as well as scenario analysis to evaluate supply-chain disruptions and tariff impacts. Validation workshops with practicing clinicians and commercial stakeholders were used to test hypotheses and refine implications for product positioning and go-to-market tactics. Throughout the methodology, emphasis was placed on triangulating insights across multiple data sources to reduce single-source bias and to ensure relevance across diverse regional contexts.

A concise synthesis of convergence between clinical innovation, regulatory expectations, and commercial execution that outlines strategic priorities for the future

Postoperative pain management for companion animals is at an inflection point where clinical best practices, formulation advances, and shifting commercial channels converge to create new opportunities and obligations for stakeholders. The move toward multimodal analgesia, coupled with innovations in extended-release local anesthetics and transdermal delivery systems, enhances the capacity to deliver effective, owner-friendly pain control. At the same time, regulatory emphasis on opioid stewardship and evolving tariff landscapes demand more sophisticated supply-chain and clinical governance approaches.

Successfully navigating this landscape requires integrating rigorous clinical evidence with channel-aware commercialization and resilient sourcing strategies. Companies that invest in clinician engagement, differentiated formulations that solve practical problems, and robust pharmacovigilance frameworks will be better positioned to influence prescribing behavior and to achieve longer-term adoption. In essence, the future of companion animal postoperative analgesia will reward organizations that pair clinical credibility with operational excellence and a clear focus on practitioner and pet-owner needs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growth of liposomal bupivacaine formulations extending postoperative analgesia in dogs and cats
  • 5.2. Adoption of opioid-sparing multimodal pain management protocols integrating NSAIDs and local blocks
  • 5.3. Emergence of wearable sensor technology for remote monitoring of postoperative pain behaviors in pets
  • 5.4. Growing interest in regenerative medicine adjuncts such as stem cells for enhanced postoperative recovery
  • 5.5. Increasing availability of veterinarian-prescribed cannabidiol preparations for managing surgical pain in companion animals
  • 5.6. Integration of telehealth platforms for virtual pain assessments and owner education in postoperative care
  • 5.7. Development of pharmacogenomic-based dosing tools to personalize analgesic regimens in veterinary practice
  • 5.8. Regulatory advancements facilitating faster approval of novel veterinary analgesics under conditional licensing pathways

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Companion Animal Postoperative Pain Management Therapeutics Market, by Product Type

  • 8.1. Local Anesthetics
    • 8.1.1. Bupivacaine
    • 8.1.2. Lidocaine
  • 8.2. Non-Steroidal Anti-Inflammatory Drugs
    • 8.2.1. Carprofen
    • 8.2.2. Deracoxib
    • 8.2.3. Firocoxib
    • 8.2.4. Meloxicam
  • 8.3. Opioids
    • 8.3.1. Buprenorphine
    • 8.3.2. Fentanyl
    • 8.3.3. Tramadol

9. Companion Animal Postoperative Pain Management Therapeutics Market, by Animal Type

  • 9.1. Cats
  • 9.2. Dogs

10. Companion Animal Postoperative Pain Management Therapeutics Market, by Route Of Administration

  • 10.1. Injectable
  • 10.2. Oral
  • 10.3. Topical
  • 10.4. Transdermal Patch

11. Companion Animal Postoperative Pain Management Therapeutics Market, by End User

  • 11.1. Online Pharmacies
  • 11.2. Veterinary Hospitals And Clinics
    • 11.2.1. General Practices
    • 11.2.2. Specialty Hospitals
  • 11.3. Veterinary Retail Pharmacies
    • 11.3.1. Chain Pharmacies
    • 11.3.2. Independent Pharmacies

12. Companion Animal Postoperative Pain Management Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Companion Animal Postoperative Pain Management Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Companion Animal Postoperative Pain Management Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Zoetis Inc.
    • 15.3.2. Elanco Animal Health Incorporated
    • 15.3.3. Merck & Co., Inc.
    • 15.3.4. Boehringer Ingelheim International GmbH
    • 15.3.5. Dechra Pharmaceuticals PLC
    • 15.3.6. Norbrook Laboratories Ltd.
    • 15.3.7. Vetoquinol SA
    • 15.3.8. Ceva Sante Animale SA
    • 15.3.9. Virbac SA
    • 15.3.10. Johnson & Johnson Services, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPIVACAINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPIVACAINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPIVACAINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPIVACAINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPIVACAINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPIVACAINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LIDOCAINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LIDOCAINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LIDOCAINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LIDOCAINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LIDOCAINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LIDOCAINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CARPROFEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CARPROFEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CARPROFEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CARPROFEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CARPROFEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CARPROFEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DERACOXIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DERACOXIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DERACOXIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DERACOXIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DERACOXIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DERACOXIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FIROCOXIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FIROCOXIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FIROCOXIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FIROCOXIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FIROCOXIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FIROCOXIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY MELOXICAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY MELOXICAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY MELOXICAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY MELOXICAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY MELOXICAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY MELOXICAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPRENORPHINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPRENORPHINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPRENORPHINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPRENORPHINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPRENORPHINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPRENORPHINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FENTANYL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FENTANYL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FENTANYL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FENTANYL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FENTANYL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FENTANYL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRAMADOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRAMADOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRAMADOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRAMADOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRAMADOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRAMADOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CATS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CATS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CATS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CATS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CATS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DOGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DOGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DOGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DOGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DOGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRANSDERMAL PATCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRANSDERMAL PATCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRANSDERMAL PATCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRANSDERMAL PATCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRANSDERMAL PATCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRANSDERMAL PATCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GENERAL PRACTICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GENERAL PRACTICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GENERAL PRACTICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GENERAL PRACTICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GENERAL PRACTICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GENERAL PRACTICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SPECIALTY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SPECIALTY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SPECIALTY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SPECIALTY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SPECIALTY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SPECIALTY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA C